Off-the-Shelf immune cells battle tough leukemia in new trial

NCT ID NCT04150497

Summary

This study is testing a new type of cell therapy called UCART22 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatments. The main goals are to find a safe and effective dose and see if the treatment can help control the cancer. UCART22 uses specially engineered immune cells from a donor, designed to find and attack the patient's leukemia cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Rennes - Hopital Pontchaillou

    RECRUITING

    Rennes, 35033, France

  • CHU de Nantes - Hôtel-Dieu

    RECRUITING

    Nantes, 44093, France

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Hôpital Lyon Sud

    RECRUITING

    Pierre-Bénite, 69310, France

  • Hôpital Robert Debré - Service d'hémato-immunologie

    RECRUITING

    Paris, 75019, France

  • Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie

    RECRUITING

    Paris, 75010, France

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14263, United States

  • Sarah Cannon - Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Sarah Cannon - HCA Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon - St. David's South Austin Medical Center

    RECRUITING

    Austin, Texas, 78704, United States

  • Sarah Cannon - Texas Transplant Institute at Methodist Hospital

    RECRUITING

    San Antonio, Texas, 78229, United States

  • University of California, Los Angeles (UCLA) - Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60647, United States

  • University of Colorado - Aurora Cancer Center

    RECRUITING

    Aurora, Colorado, 80045, United States

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • Weill Medical College of Cornell University

    WITHDRAWN

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.